Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Oncolytics receives U.K. approval to initiate phase II clinical trial of Reolysin in cancer

May 16, 2008

New therapeutic agents for cancer reported in recent patent literature

May 16, 2008

Novel VEGFR-2 inhibitor profiled at Bristol-Myers Squibb

May 16, 2008

Health Canada grants approval to Thallion to initiate phase II clinical trial of TLN-4601

May 16, 2008

FDA grants orphan drug designation for SB-1518 in myeloproliferative disorders

May 15, 2008

New therapeutic options for cancer reported in recent patents

May 15, 2008

Oncolytics initiates enrollment in REO 012 clinical trial of Reolysin and cyclophosphamide

May 15, 2008

CY-503 evaluated in phase II stage IV malignant melanoma trial

May 15, 2008

Novelos presents positive results in ongoing phase II neoadjuvant breast cancer trial

May 14, 2008

Recent patent literature discloses new treatment options for cancer

May 14, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...